阿哌沙班与华法林起始治疗对透析合并新发房颤患者的比较:目标试验模拟
该研究基于美国肾脏数据系统模拟随机对照试验,比较透析合并新发房颤患者起始阿哌沙班或华法林的疗效与安全性。倾向匹配后分析显示,阿哌沙班组缺血性卒中风险降低34%,临床重要出血风险降低28%,全因死亡无差异。
要点
- 透析合并新发房颤患者起始阿哌沙班较华法林卒中风险更低。
- 阿哌沙班较华法林临床重要出血风险降低28%。
- 两组全因死亡及阴性对照结局无显著差异。
核心结论
- 在新发房颤的透析患者中,起始阿哌沙班较华法林与更低的缺血性卒中和临床重要出血风险相关。
研究设计与样本
- 基于美国肾脏数据系统的目标试验模拟,纳入2014-2019年Medicare保险的透析合并新发房颤且近期未用抗凝药患者。
- 比较房颤诊断后30天内起始阿哌沙班或华法林,采用倾向性评分匹配后Cox比例风险模型分析。
主要发现
- 共3985例起始阿哌沙班和6426例起始华法林,倾向匹配各3978例,中位CHA2DS2-VASc评分为4(IQR 3-5)。
- 意向性治疗分析中,阿哌沙班组缺血性卒中发生率降低34%(HR 0.66;95%CI 0.47-0.94;p=0.02)。
- 阿哌沙班组临床重要出血发生率降低28%(HR 0.72;95%CI 0.63-0.83;p<0.001)。
- 全因死亡、髋部骨折和肺炎阴性对照结局在两组间无差异。
- 限制于CHA2DS2-VASc评分≥2的患者,结果稳健。
临床怎么用
- 对于透析合并新发房颤且适合抗凝的患者,可考虑优先起始阿哌沙班而非华法林以降低卒中和出血风险。
局限性
- 存在残余混杂可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Patients with kidney failure on hemodialysis (KFHD) and atrial fibrillation (AF) are at high risk of ischemic stroke. Oral anticoagulation (OAC) may reduce this risk but at the expense of excess bleeding. We emulated a randomized comparative effectiveness trial of apixaban versus warfarin initiation in patients with KFHD and newly diagnosed AF. STUDY DESIGN: Trial emulation embedded in the US Renal Data System. SETTING & PARTICIPANTS: Medicare-insured patients with KFHD and newly diagnosed AF without recent OAC use (2014-2019). EXPOSURES: Initiation of apixaban versus warfarin within 30 days from AF diagnosis. OUTCOMES: Ischemic stroke, clinically important bleeding (co-primary outcomes). Other thromboembolic and bleeding events, death (secondary). ANALYTICAL APPROACH: We compared propensity-matched new users of apixaban and warfarin using Cox proportional hazards models. RESULTS: Among previously OAC-naïve patients with KFHD and newly diagnosed with AF, 3985 initiated apixaban and 6426 initiated warfarin. Propensity matching 3978 apixaban users with 3978 warfarin users balanced all measured characteristics. Median CHA2DS2-VASc score was 4 (IQR: 3-5). Apixaban was initiated a median 6 (IQR: 3-12) days after AF and used for a median 58 (IQR:37-135) days; warfarin was initiated a median 5 (IQR: 2-12) days after AF and used for a median 93 (IQR:38-238) days. In intention-to-treat analyses, rates of ischemic stroke were 34% lower (HRITT=0.66; 95%CI, 0.47-0.94; p=0.02) and rates of clinically important bleeding were 28% lower (HRITT=0.72; 95%CI, 0.63-0.83; p<0.001) in patients who initiated apixaban. All-cause mortality did not differ between groups; neither did negative control outcomes of hip fracture and pneumonia. Results were robust when restricting analyses to patients with CHA2DS2-VASc score of ≥2. LIMITATIONS: Potential for residual confounding. CONCLUSIONS: Initiating apixaban soon after newly diagnosed AF was associated with lower risks of ischemic stroke and clinically important bleeding compared with initiating warfarin.
引用
- Winkelmayer WC, Montez-Rath ME, He M, et al. Initiation of Apixaban Versus Warfarin in Patients With Kidney Failure on Hemodialysis With Newly Diagnosed Atrial Fibrillation: A Target Trial Emulation. Am J Kidney Dis. 2026. PMID: 42906734. doi:10.1053/j.ajkd.2026.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。